Biodesix
Biodesix, Inc.: A leading biotech firm providing data-driven diagnostic solutions and lab tests in the US.
Founded
2005Biodesix, Inc.: A leading biotech firm providing data-driven diagnostic solutions and lab tests in the US.
Biodesix, Inc., founded with a mission to improve patient outcomes through innovative diagnostic solutions, focuses on providing data-driven, blood-based tests for lung cancer. Their core products include the Nodify Lung® testing suite, which comprises the Nodify CDT® and Nodify XL2® tests for assessing lung nodule malignancy risk, and the IQLung Treatment Guidance testing suite, featuring GeneStrat® targeted tests, GeneStrat NGS™ genomic tests, and VeriStrat® proteomic tests. These tools enable healthcare providers to make informed decisions quickly and confidently, enhancing patient care in the United States.
Notable figures associated with Biodesix include its experienced leadership team and a network of investors committed to advancing biotech innovations. The company has achieved significant milestones, such as developing proprietary proteomic and genomic testing technologies that deliver rapid results. Biodesix's impact is evident in its contribution to personalized medicine, particularly in the field of non-small cell lung cancer diagnostics, where it helps clinicians tailor treatments to individual patient profiles, ultimately improving clinical outcomes and patient quality of life.
Companies similar to Biodesix include Castle Biosciences, Veracyte, LungLife AI and Predictive Biosciences.
Biodesix was founded in 2005.
Biodesix's headquarters is located in Boulder, CO, US.
Biodesix's most recent funding round was for $40.3M (USD) in November 2022.
As of Nov 17, 2022, Biodesix has disclosed funding of $390.3M (USD). Undisclosed round amounts are excluded.
Biodesix has 245 employees as of Feb 6, 2024.
Predictive Biosciences
